Northwestern Mutual Wealth Management Co. Takes Position in DexCom, Inc. $DXCM

Northwestern Mutual Wealth Management Co. acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,487 shares of the medical device company’s stock, valued at approximately $639,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Reflection Asset Management bought a new position in DexCom during the fourth quarter worth about $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom in the first quarter valued at about $25,000. MCF Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $32,000. Wellington Grp LLC boosted its position in DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new position in DexCom in the fourth quarter valued at about $36,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,035 shares of company stock worth $5,446,673 over the last three months. Company insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on DXCM shares. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research note on Friday, May 1st. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Argus raised their price target on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Barclays restated an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Wells Fargo & Company increased their price target on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Stock Performance

NASDAQ DXCM opened at $88.96 on Thursday. The company has a market capitalization of $33.57 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 1.50 and a beta of 1.41. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock has a fifty day simple moving average of $78.50 and a 200 day simple moving average of $71.33. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.48 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.